These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25771402)

  • 1. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.
    Baird K; Comis LE; Joe GO; Steinberg SM; Hakim FT; Rose JJ; Mitchell SA; Pavletic SZ; Figg WD; Yao L; Flanders KC; Takebe N; Sarantopoulos S; Booher S; Cowen EW
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1083-90. PubMed ID: 25771402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease.
    Choi JY; Kim H; Baek HJ; Kook H; Lee JM; Kim BK; An HY; Hong KT; Shin HY; Kang HJ
    Transplant Cell Ther; 2021 Nov; 27(11):925.e1-925.e7. PubMed ID: 34314892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
    Sánchez-Ortega I; Servitje O; Arnan M; Ortí G; Peralta T; Manresa F; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):318-23. PubMed ID: 22068151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.
    Sánchez-Ortega I; Parody R; Servitje O; Muniesa C; Arnan M; Patino B; Sureda A; Duarte RF
    Croat Med J; 2016 Jun; 57(3):247-54. PubMed ID: 27374826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.
    Rosenthal EA; Ho PS; Joe GO; Mitchell SA; Booher S; Pavletic SZ; Baird K; Cowen EW; Comis LE
    Support Care Cancer; 2020 Aug; 28(8):3679-3689. PubMed ID: 31811481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
    Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I
    Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease.
    Sorenson E; McAndrew R; Patel V; Logan AC; Koo J; Levin E
    JAMA Dermatol; 2015 Jun; 151(6):635-7. PubMed ID: 25806783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease.
    Richet C; Huynh A; Dimeglio C; Borel C; Lepage B; Boulinguez S; Marguery MC; Paul C; Bulai Livideanu C
    Dermatology; 2018; 234(1-2):23-30. PubMed ID: 29788024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.
    Arai S; Pidala J; Pusic I; Chai X; Jaglowski S; Khera N; Palmer J; Chen GL; Jagasia MH; Mayer SA; Wood WA; Green M; Hyun TS; Inamoto Y; Storer BE; Miklos DB; Shulman HM; Martin PJ; Sarantopoulos S; Lee SJ; Flowers ME
    Clin Cancer Res; 2016 Jan; 22(2):319-27. PubMed ID: 26378033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
    Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.
    Magro L; Mohty M; Catteau B; Coiteux V; Chevallier P; Terriou L; Jouet JP; Yakoub-Agha I
    Blood; 2009 Jul; 114(3):719-22. PubMed ID: 19289852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zhang FH; Ling YW; Zhai X; Zhang Y; Huang F; Fan ZP; Zhou HS; Jiang QL; Sun J; Liu QF
    Hematology; 2013 May; 18(3):151-7. PubMed ID: 23394269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.
    Martires KJ; Baird K; Steinberg SM; Grkovic L; Joe GO; Williams KM; Mitchell SA; Datiles M; Hakim FT; Pavletic SZ; Cowen EW
    Blood; 2011 Oct; 118(15):4250-7. PubMed ID: 21791415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH).
    Parra Salinas I; Bermudez A; López Corral L; Lopez Godino O; Móles-Poveda P; Martín G; Costilla Barriga L; Ferrá Coll C; Márquez-Malaver F; Ortí G; Zudaire Ripa MT; Rifon J; Martinez C;
    Clin Transplant; 2021 May; 35(5):e14255. PubMed ID: 33595866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
    Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
    Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation.
    Inagaki J; Kodama Y; Fukano R; Noguchi M; Okamura J
    Pediatr Transplant; 2015 Sep; 19(6):652-8. PubMed ID: 26103520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.